ORPHA:85438
Enthesitis-related juvenile idiopathic arthritis
Also known as: Enthesitis-related JIA · Juvenile ERA
Publications
199
63.1th percentile
Trials
0
Interventional, condition-specific
Researchers
1,168
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare inflammatory rheumatic disease in a child younger than 16 years characterized by arthritis and/or enthesitis and/or acute anterior uveitis. The most commonly affected joints at diagnosis are the knees, ankles, and hips. The small joints of the feet and toes are also often involved.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019437
- UMLS:C3495919
- NCIT:C119024
Additional Mondo synonyms (3)
ERA · enthesitis-related JIA · era
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
199 matched papers (146 in last 10 years) Source
- Phenotype characterisedPresent
34 HPO annotations (e.g. Abnormal fascia morphology; Abnormal foot morphology; Abnormal metatarsal morphology) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 177 for broader category juvenile idiopathic arthritis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
34
Associated phenotypes · MONDO:0019437
- Abnormal fascia morphology
- Abnormal foot morphology
- Abnormal metatarsal morphology
- Abnormal shoulder morphology
- Enthesitis
Showing 5 of 34 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
6
Drugs / clinical candidates · MONDO_0019437
- ADALIMUMAB·phase 3
- BARICITINIB·phase 3
- BIMEKIZUMAB·phase 3
- ETANERCEPT·phase 3
- IXEKIZUMAB·phase 3
- TOFACITINIB·phase 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
199
199 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
199 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
146 in the last 10 years · medium confidence · 63.1th percentile (publications denominator)
Phrase hits: 199 · MeSH hits: 0
Who's working on it?
1,168
Distinct author names in 199 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Thomson W12 papers · 2021
Arthritis Research UK Centre for Genetics and Genomics, Manchester Academic Health Centre, University of Manchester, Manchester, M13 9PT, United Kingdom; National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit, Central Manchester National Health Service Foundation Trust, Manchester Academic Health Centre, University of Manchester, Manchester, M13 9PT, United Kingdom;
Papers in Europe PMC - 02Prahalad S8 papers · 2024
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322; Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322;
Papers in Europe PMC - 03Ruperto N8 papers · 2026
Pediatria II e Reumatologia, Istituto G Gaslini Genoa, University of Genoa Genoa, Italy.
Papers in Europe PMC - 04Hyrich KL7 papers · 2024
Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute for Inflammation and Repair, Faculty of Medical and Human Sciences, University of Manchester, Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK kimme.hyrich@manchester.ac.uk.
Papers in Europe PMC - 05Quartier P7 papers · 2026
Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France.
Papers in Europe PMC - 06Brunner HI6 papers · 2025
Division of Rheumatology, Cincinnati Children's Hospital Medical Center & Cincinnati Children's Research Foundation, MLC 4010, Cincinnati, OH, 45229, USA. Hermine.brunner@cchmc.org.
Papers in Europe PMC - 07Hinks A6 papers · 2015
Arthritis Research UK Centre for Genetics and Genomics, Manchester Academic Health Centre, University of Manchester, Manchester, M13 9PT, United Kingdom;
Papers in Europe PMC - 08Wedderburn LR6 papers · 2024
Institute of Child Health, University College London, London, WC1N 1EH, United Kingdom; Center of Paediatric and Adolescent Rheumatology, University College London, London, WC1N 1EH, United Kingdom;
Papers in Europe PMC - 09Bohnsack JF5 papers · 2024
Department of Pediatrics, University of Utah, Salt Lake City, UT 84113;
Papers in Europe PMC - 10Martini A5 papers · 2024
Department of Pediatrics, University of Genova, 16145 Genoa, Italy; Pediatrics II Unit, G. Gaslini Institute, 16147 Genoa, Italy;
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 177 trials are registered for juvenile idiopathic arthritis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
177 interventional trials matched juvenile idiopathic arthritis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: juvenile idiopathic arthritis
177
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07184450·RECRUITING·Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
Conditions: Juvenile Dermatomyositis (JDM) · Polyarticular Juvenile Idiopathic Arthritis · Systemic Sclerosis (SSc) · Primary Sjogren's Syndrome·Matched via name phrase
- NCT06654882·RECRUITING·Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Conditions: Polyarticular Course Juvenile Idiopathic Arthritis (JIA)·Matched via name phrase
- NCT03773965·RECRUITING·A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Conditions: Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT07553182·RECRUITING·OLE Study With Filgotinib in JIA
Conditions: Juvenile Idiopathic Arthritis (JIA)·Matched via name phrase
- NCT07087912·RECRUITING·Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Conditions: Rheumatoid Arthritis (RA) · Juvenile Idiopathic Arthritis (JIA) · Systemic Lupus Erythematosus (SLE) · Juvenile Systemic Lupus Erythematosus·Matched via name phrase
- NCT07699107·NOT YET RECRUITING·Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
Conditions: Juvenile Idiopathic Arthritis Associated Uveitis · Uveitis, Anterior·Matched via name phrase
- NCT07386587·ENROLLING BY INVITATION·Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis
Conditions: Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT06653634·RECRUITING·Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
Conditions: Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT07554495·RECRUITING·Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
Conditions: Polyarticular Course Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT07634354·NOT YET RECRUITING·Sarcopenia and Juvenile Idiopathic Arthritis
Conditions: Juvenile Idiopathic Arthritis·Matched via name phrase
- NCT06888973·ENROLLING BY INVITATION·Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases
Conditions: Rheumatoid Arthritis · Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Ankylosing Spondylitis (AS)·Matched via name phrase
- NCT01962415·RECRUITING·Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Conditions: Primary Immunodeficiency (PID) · Congenital Bone Marrow Failure Syndromes · Inherited Metabolic Disorders (IMD) · Hereditary Anemias·Matched via name phrase
- NCT06376149·RECRUITING·M3-JIA: Making Mindfulness Matter for Children With JIA
Conditions: Juvenile Idiopathic Arthritis · Children · Mental Health · Mental Well-being·Matched via name phrase
- NCT06874608·RECRUITING·Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis
Conditions: Juvenile Idiopathic Arthritis (JIA)·Matched via name phrase
- NCT07661069·NOT YET RECRUITING·YOGA FOR CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS
Conditions: Juvenile Idiopathic Arthritis (JIA)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- isrctn·ISRCTN54174557·Recruiting·Steroid Treatment Trial in JIA (STAR-JIA): A randomised trial to compare the effectiveness, safety and cost-effectiveness of intravenous versus oral corticosteroid induction regimens for children and young people with juvenile idiopathic arthritis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49107623·No longer recruiting·Study to evaluate the efficacy, pharmacokinetics, safety, and immunogenicity of subcutaneously administered ustekinumab or guselkumab in pediatric participants with active juvenile psoriatic arthritis
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Enthesitis-related juvenile idiopathic arthritis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Enthesitis-related juvenile idiopathic arthritis" OR "Enthesitis-related JIA" OR "Juvenile ERA"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Enthesitis-related juvenile idiopathic arthritis" OR "Enthesitis-related JIA" OR "Juvenile ERA"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"juvenile idiopathic arthritis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: ERA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T03:02:11.546Z
